Clinical Trials · NCT00943917
Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Intarcia Therapeutics
- Enrollment
- 155
- Start date
- Aug 2009
- Locations
- 50 sites, United States
- Primary endpoint
- Mean Change in HbA1c (Per Protocol)